LOGIN
Male glucocorticoid-induced osteoporosis: teriparatide more effective than risedronate
September 2013
Male glucocorticoid-induced osteoporosis: teriparatide more effective than risedronate
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial
J Bone Miner Res. 2013 Jun;28(6):1355-68. doi: 10.1002/jbmr.1870Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
92 men with glucocorticoid-induced osteoporosis (GIO) were randomized to receive either daily injections of 20 ug teriparatide or weekly oral tablets of 35 mg risedronate to determine the effects of these treatments on improvements in bone mineral density (BMD), as assessed with dual X‐ray absorptiometry (DXA) and high-resolution quantitative computed tomography (HRQCT). Results indicated that, al...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.